Skip to main content
. 2019 Dec 26;12(1):74. doi: 10.3390/cancers12010074

Figure 1.

Figure 1

Higher number of OXi4503 doses administered is associated with improved survival outcome. The median OS time for 18 patients receiving 1–3 doses of OXi4503 was 82 (95% CI: 66–135) days and these patients exhibited a worse survival outcome compared to 9 patients receiving 4–6 doses which was recorded at 434 (95% CI: 191–NA) days (Log Rank χ2 = 12.3, p-value = 0.0004).